arrow
P

Peter J. Greasley

biopharmaceuticals r&d
H指数:36
被引数:8,538

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SGLT2 inhibition triggers aestivation-like metabolic switches for water conservation in patients with heart failure-results from DAPA-Shuttle1, a randomized, placebo-controlled trial

SGLT2抑制可触发心衰患者为保水而进行的休眠样代谢转换——DAPA-Shuttle1随机、安慰剂对照试验的结果

2025-10-010
PRE
Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease; primary sclerosing cholangitis

内皮素受体拮抗剂和钠-葡萄糖共转运蛋白2抑制剂在慢性肝病;原发性硬化性胆管炎中的治疗靶点定位

2025-09-290
OAAI
A multi-omics microbiome signature is associated with the benefits of gastric bypass surgery and is differentiated from diet induced weight loss through 2 years of follow-up

多组学微生物组特征与胃旁路手术的益处相关,且在为期2年的随访中与饮食诱导的体重减轻存在差异。

2025-04-110
OAAI
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

Zibotentan联合dapagliflozin与dapagliflozin在慢性肾脏病 (zenih-ckd) 患者中的比较: 一项多中心,随机,主动对照,2b期临床试验

LANCET
IF88.5
2023-11-0150
OAAI